Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

New analysis highlights growing trends in combination cancer therapy clinical trials

The Cancer Research Institute, a nonprofit organization dedicated to the discovery and development of powerful immunotherapies for all types of cancer, announced today the publication of its newest analysis of the global landscape of clinical development of drugs that target the PD1/PDL1 immune checkpoint pathway.

10 Feb 2022

Persistent Ebola virus can hide in the brain and re-emerge to cause fatal disease

In a groundbreaking study published today, scientists describe how Ebola virus, which can persist in certain areas of the body, can re-emerge to cause fatal disease - even long after treatment with monoclonal antibodies.

9 Feb 2022

Single-cell sequencing provides detailed insight into early SARS-CoV-2 infection in the lungs

What is going on at the single-cell level in the first days of SARS-CoV-2 infection in the lungs?

9 Feb 2022

Memory B cells induced by mRNA vaccine may help generate antibodies against Omicron

In a recent research article published in the journal of Science Immunology, a team of researchers from Japan performed longitudinal analysis on the cellular composition of receptor-binding domain (RBD) memory B cell subsets and its antibody binding and neutralizing activity against the Beta, Delta, and Omicron variants following the second dose of a messenger ribonucleic acid (mRNA) vaccine.

8 Feb 2022

Innate immune processes involved in SARS-CoV-2 recognition and resultant inflammation

A new article reviewed the innate immune detection and signaling pathways that the host uses against SARS-CoV-2.

7 Feb 2022

Older people at highest risk of death are least likely to receive effective COVID-19 treatment

People over age 65 at the highest risk for severe COVID-19 have often been the least likely to receive monoclonal antibodies (mAbs)—a highly effective treatment for the disease—both across and within U.S. states, according to new research co-authored by researchers from Harvard T.H. Chan School of Public Health.

4 Feb 2022

Wistar researchers takes a promising step in the direction of developing HIV vaccine

Nearly four decades after its discovery, HIV has killed 36.3 million people, with no vaccine in sight. However, a new study by researchers at The Wistar Institute, an international biomedical research leader in cancer, immunology, infectious disease, and vaccine development, takes a promising step in the direction of developing an HIV vaccine.

4 Feb 2022

Researchers develop influenza virus-like particle-based hybrid vaccine for both influenza and SARS-CoV-2 viruses

In a new study, a team of researchers developed a hybrid vaccine for SARS-CoV-2 and influenza viruses using influenza virus-like particles (VLP).

4 Feb 2022

Researchers suggest that visible blue light is a safe and variant-agnostic therapy against SARS-CoV-2

In a new study, researchers showed that 425 nm blue light can inactivate all major SARS CoV 2 variants.

4 Feb 2022

Rapid antigen test for SARS-CoV-2 shows lower sensitivity

In a new study, researchers assessed a rapid antigen (Ag) test for SARS-CoV-2.

2 Feb 2022

SARS-CoV-2 entry at the cell surface facilitated by trypsin

Exogenous trypsin treatment boosts SARS-CoV-2 infection in Vero E6 cells and promotes viral multiplication in cultured cells.

1 Feb 2022

Study finds limited evidence for IL-1 blockers in treating COVID-19

Researchers assess the effectiveness and safety outcomes of interleukin-1 blocking agents in the treatment of COVID-19.

31 Jan 2022

UK's most vulnerable will soon be able to access second ground-breaking antiviral

Thousands of the country's most vulnerable will be able to access the UK's second ground-breaking antiviral - Pfizer's PF-07321332+ritonavir (Paxlovid) - from Thursday 10 February, the government has announced today.

28 Jan 2022

E406W mutation on SARS-CoV-2 RBD escapes monoclonal antibody cocktail-mediated neutralization

Researchers look to better understand the molecular basis of E406W-mediated escape from the REGEN-COV cocktail and cilgavimab.

28 Jan 2022

Novel molecular signaling pathway plays a key role in producing osteoarthritis pain

Researchers from North Carolina State University have discovered that a particular molecular signaling pathway plays an important role in producing osteoarthritis (OA) pain.

27 Jan 2022

Evaluating the effectiveness of vaccination on the case fatality rate for COVID-19 infection

A recent study was published where CFR was assessed for COVID-19 vaccine effectivity

27 Jan 2022

Evaluating the use of megadoses of corticosteroids as a treatment of COVID-19

In a new study, researchers have been investigating the effects of megadoses of corticosteroids on hospitalized COVID-19 patients.

26 Jan 2022

Beta-amyloid deposits found in young patients with COVID-19

A new study describes the finding that patients of COVID-19 exhibit large amounts of focal β-amyloid deposits in their neocortical tissues.

25 Jan 2022

Hospitalized COVID-19 patients may derive modest benefit from convalescent plasma, study shows

Transfusions of blood plasma donated by people who have recovered from COVID-19 may help patients hospitalized with the virus, a new international study shows.

25 Jan 2022

Alpaca-derived antibody fragment disrupts interaction between SARS-CoV-2 spike protein and human ACE2

Researchers have been investigating the potential for using nanobodies – special immune particles from llamas and alpacas – against the disease.

24 Jan 2022

Monoclonal Antibody News and Research

Further Reading

New analysis highlights growing trends in combination cancer therapy clinical trials

Persistent Ebola virus can hide in the brain and re-emerge to cause fatal disease

Single-cell sequencing provides detailed insight into early SARS-CoV-2 infection in the lungs

Memory B cells induced by mRNA vaccine may help generate antibodies against Omicron

Innate immune processes involved in SARS-CoV-2 recognition and resultant inflammation

Older people at highest risk of death are least likely to receive effective COVID-19 treatment

Wistar researchers takes a promising step in the direction of developing HIV vaccine

Researchers develop influenza virus-like particle-based hybrid vaccine for both influenza and SARS-CoV-2 viruses

Researchers suggest that visible blue light is a safe and variant-agnostic therapy against SARS-CoV-2

Rapid antigen test for SARS-CoV-2 shows lower sensitivity

SARS-CoV-2 entry at the cell surface facilitated by trypsin

Study finds limited evidence for IL-1 blockers in treating COVID-19

UK's most vulnerable will soon be able to access second ground-breaking antiviral

E406W mutation on SARS-CoV-2 RBD escapes monoclonal antibody cocktail-mediated neutralization

Novel molecular signaling pathway plays a key role in producing osteoarthritis pain

Evaluating the effectiveness of vaccination on the case fatality rate for COVID-19 infection

Evaluating the use of megadoses of corticosteroids as a treatment of COVID-19

Beta-amyloid deposits found in young patients with COVID-19

Hospitalized COVID-19 patients may derive modest benefit from convalescent plasma, study shows

Alpaca-derived antibody fragment disrupts interaction between SARS-CoV-2 spike protein and human ACE2

Antibodies eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®